Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRTC.LSE
- Price
- 103.00
- Stock movement up
- +- (%)
- Company name
- PureTech Health plc
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 24.66B
- Ent value
- 24.63B
- Price/Sales
- 52693.08
- Price/Book
- 80.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.33%
- 1 year return
- -51.76%
- 3 year return
- -19.84%
- 5 year return
- -16.94%
- 10 year return
- -
Last updated: 2025-04-11
DIVIDENDS
PRTC.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 52693.08 |
| Price to Book | 80.54 |
| EV to Sales | 52618.86 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 239.42M |
| EPS (TTM) | -0.31 |
| FCF per share (TTM) | -0.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 468.00K |
| Gross profit (TTM) | -81.55M |
| Operating income (TTM) | -136.43M |
| Net income (TTM) | -82.47M |
| EPS (TTM) | -0.31 |
| EPS (1y forward) | -0.55 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -17425.00% |
| Operating margin (TTM) | -29152.78% |
| Profit margin (TTM) | -17620.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 308.48M |
| Net receivables | 2.06M |
| Total current assets | 508.81M |
| Goodwill | 0.00 |
| Intangible assets | 906.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 579.95M |
| Accounts payable | 8.13M |
| Short/Current long term debt | 144.73M |
| Total current liabilities | 138.31M |
| Total liabilities | 273.74M |
| Shareholder's equity | 306.21M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -120.80M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -120.80M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -26.93% |
| Return on Assets | -14.22% |
| Return on Invested Capital | -26.01% |
| Cash Return on Invested Capital | -38.10% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 113.20 |
| Daily high | 115.80 |
| Daily low | 101.40 |
| Daily Volume | 1.99M |
| All-time high | 425.50 |
| 1y analyst estimate | 490.63 |
| Beta | 0.99 |
| EPS (TTM) | -0.31 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 23 Apr 2025 |
Downside potential
Loading...
Downside potential data
| PRTC.LSE | S&P500 | |
| Current price drop from All-time high | -75.79% | -14.41% |
| Highest price drop | -75.79% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -29.03% | -11.07% |
| Avg time to new high | 39 days | 12 days |
| Max time to new high | 1036 days | 1805 days |
COMPANY DETAILS
Marketcap
24.66B
Marketcap category
Large-cap
Description
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Employees
90
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found